ReviewGlobal spine journal2017
Efficacy and Safety of Methylprednisolone Sodium Succinate in Acute Spinal Cord Injury: A Systematic Review.
Review in Global spine journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 130 citations in OpenAlex.
- A reparative neutrophil subpopulation accelerates spinal cord regeneration in zebrafish by controlling macrophage inflammation via Il-4.Journal of neuroinflammation · 2026Article
- Advances in Hydrogel Tissue Engineering for Spinal Cord Injury Repair.Smart medicine · 2026Review
- Bidirectional communication between spinal cord injury and gut microbiota, from the bench to the bedside.Frontiers in immunology · 2026Review
- Neural stem cell-derived extracellular vesicles drive early neuroprotective and anti-apoptotic responses in spinal cord injury organotypic slices.Frontiers in cellular neuroscience · 2026Article
- Copper-regulated cell death after spinal cord injury: evidence boundaries for non-coding RNA, epigenetics and cuproptosis.Frontiers in molecular neuroscience · 2026Review
- Clinical Recommendations for the Acute Care of Patients With Traumatic Spinal Cord Injury.Deutsches Arzteblatt international · 2025Review
- Identification and Management of Neurologic Complications in Patients Undergoing Adult Spinal Deformity Surgery.Global spine journal · 2025Article
- Traumatic spinal cord injury: a review of the current state of art and future directions - what do we know and where are we going?North American Spine Society journal · 2025Article
- Advances and New Therapies in Traumatic Spinal Cord Injury.Journal of clinical medicine · 2025Review
- Cationic Liposome-Mediated Bcl-2 Gene Transfection in Bone Marrow Mesenchymal Stem Cells: A Novel Regenerative Approach for Spinal Cord Injury.Drug design, development and therapy · 2025Article
- High-dose preoperative intraperitoneal erythropoietin and intravenous methylprednisolone in acute traumatic spinal cord injuries following decompression surgeries.Open medicine (Warsaw, Poland) · 2025Article
- Delivery of TGFβ3 from Magnetically Responsive Coaxial Fibers Reduces Spinal Cord Astrocyte Reactivity In Vitro.Advanced biology · 2024Article
- Spinal cord injury in high-risk complex adult spinal deformity surgery: review of incidence and outcomes from the Scoli-RISK-1 study.Spinal cord series and cases · 2024Article
- Blockade of the ADAM8-Fra-1 complex attenuates neuroinflammation by suppressing the Map3k4/MAPKs axis after spinal cord injury.Cellular & molecular biology letters · 2024Article
- Clinical characteristics analysis of pediatric spinal cord injury without radiological abnormality in China: a retrospective study.BMC pediatrics · 2024Article
- The role of small extracellular vesicles and microRNA as their cargo in the spinal cord injury pathophysiology and therapy.Frontiers in neuroscience · 2024Review
- A 3D-Printed Dual Driving Forces Scaffold with Self-Promoted Cell Absorption for Spinal Cord Injury Repair.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- bFGF-like Activity Supported Tissue Regeneration, Modulated Neuroinflammation, and Rebalanced CaInternational journal of molecular sciences · 2023Article
- Spinal cord injury: molecular mechanisms and therapeutic interventions.Signal transduction and targeted therapy · 2023Review
- The Role of Aquaporins in Spinal Cord Injury.Cells · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
STUDY
designSystematic review and meta-analysis.
objectiveThe objective of this study was to conduct a systematic review to assess the comparative effectiveness and safety of high-dose methylprednisolone sodium succinate (MPSS) versus no pharmacological treatment in patients with traumatic spinal cord injury (SCI).
methodsA systematic search was performed in PubMed and the Cochrane Collaboration Library for literature published between January 1956 and June 17, 2015. Included studies were critically appraised, and Grades of Recommendation Assessment, Development and Evaluation methods were used to determine the overall quality of evidence for primary outcomes. Previous systematic reviews on this topic were collated and evaluated using the Assessment of Multiple Systematic Reviews scoring system.
resultsThe search yielded 723 citations, 13 of which satisfied inclusion criteria. Among these, 6 were primary research articles and 7 were previous systematic reviews. Based on the included research articles, there was moderate evidence that the 24-hour NASCIS II (National Acute Spinal Cord Injury Studies) MPSS regimen has no impact on long-term neurological recovery when all postinjury time points are considered. However, there is also moderate evidence that subjects receiving the same MPSS regimen within 8 hours of injury achieve an additional 3.2 points (95% confidence interval = 0.10 to 6.33;
conclusionAlthough safe to administer, a 24-hour NASCIS II MPSS regimen, when all postinjury time points are considered, has no impact on indices of long-term neurological recovery. When commenced within 8 hours of injury, however, a high-dose 24-hour regimen of MPSS confers a small positive benefit on long-term motor recovery and should be considered a treatment option for patients with SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.